[引用][C] APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria
D El Mehdi, FV Grossi, P Deschatelets, H Pullon… - Molecular …, 2017 - Elsevier
[HTML][HTML] Evaluation of the long-term safety and efficacy of pegcetacoplan treatment for paroxysmal nocturnal hemoglobinuria patients: an extension study
K Hoffman, Z Machaidze, M Yeh, IC Weitz - Blood, 2021 - Elsevier
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, potentially life-
threatening disease characterized by complement mediated hemolysis and thrombosis …
threatening disease characterized by complement mediated hemolysis and thrombosis …
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
AE DeZern, D Dorr, RA Brodsky - European journal of …, 2013 - Wiley Online Library
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, hematopoietic stem
cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has …
cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has …
Current opinions on the clinical utility of ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria
C Gurnari, I Nautiyal, S Pagliuca - Therapeutics and Clinical Risk …, 2021 - Taylor & Francis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder of hematopoietic stem cells
genetically defined by the acquisition of somatic mutations in the X-linked …
genetically defined by the acquisition of somatic mutations in the X-linked …
Ravulizumab Provides Durable Control of Intravascular Hemolysis and Improves Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Follow …
A Kulasekararaj, H Schrezenmeier, K Usuki, A Kulagin… - Blood, 2023 - Elsevier
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare chronic blood disorder
characterized by uncontrolled terminal complement activation, leading to intravascular …
characterized by uncontrolled terminal complement activation, leading to intravascular …
[HTML][HTML] Pozelimab, a human monoclonal antibody against complement factor C5, provided inhibition of intravascular hemolysis in patients with paroxysmal nocturnal …
JH Jang, J Weyne, U Chaudhari, O Harari, J Miller… - Blood, 2021 - Elsevier
Abstract INTRODUCTION Paroxysmal Nocturnal hemoglobuinuria (PNH) is a rare, acquired,
life-threatening disorder characterised by intravascular hemolysis and increased risk of …
life-threatening disorder characterised by intravascular hemolysis and increased risk of …
Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria
A Hill, SJ Richards, RP Rother, P Hillmen - Haematologica, 2007 - haematologica.org
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis
leading to anemia and other clinical manifestations. Transfusions are often required to …
leading to anemia and other clinical manifestations. Transfusions are often required to …
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study
M Loschi, R Porcher, F Barraco… - American Journal of …, 2016 - Wiley Online Library
Intravascular hemolysis in Paroxysmal nocturnal hemoglobinuria (PNH) can effectively be
controlled with eculizumab, a humanized monoclonal antibody that binds complement …
controlled with eculizumab, a humanized monoclonal antibody that binds complement …
[HTML][HTML] Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal …
RA Brodsky, RP De Latour, ST Rottinghaus… - …, 2021 - ncbi.nlm.nih.gov
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however,
approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on …
approximately 11-27% of patients may experience breakthrough hemolysis (BTH) on …